Rofecoxib, a nonsteroidal antiinflammatory agent, is a selective inhibitor of cyclooxygenase 2 with analgesic and antipyretic activities. Its pharmacological effects are thought to be due to reduction of prostaglandin synthesis. Merck and Co. Inc. voluntarily withdrew product (Vioxx) from the global market in September of 2004 after a colon cancer trial confirmed concerns the drug raises the risk of .... © 2007 Elsevier Inc.
Miles, S. (2011). Rofecoxib. In xPharm: The Comprehensive Pharmacology Reference (pp. 1–6). Elsevier Inc. https://doi.org/10.1016/B978-008055232-3.62555-3